World Health Organization (WHO) · Journal articles

Weekly Epidemiological Record, 2010, vol. 85, 22 [full issue]

World Health Organization
View original document

The full text is hosted by the publishing organisation. lawenc.com indexes the metadata and links to the official source.

Full text

– 2010

/

(SAGE)

(SAGE) 1

. . 2010 / 15 13

:

.(SAGE)

(SAGE)

– 2010 . 2015 .

(1 :

.

2010 .

.

1

http://www.who.int/immunization/sage/en/index.html, accessed May 2010).(

1

(2 . ( .( . ( ) ) )

(SAGE)

) 2010 .(

/ 2015

/ .2010 /

. . 2010

.

2010 .(SAGE) . .

/

26

2

(SAGE)

.

5 . (SAGE) .

.

strain

.

replacement

GAVI

. . .

. ) 3

(ProVac

2

. 2009 3

15 (SAGE)

2010

/

Vaccine

. . .

: .2010 ( 2011 . 58 72 )

2009

/ (AMC)

1500 .

.

2

Andrus JK et al. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Reports, 2007, 122:811–816.

Nelson EAS et al. The role of national advisory committees in supporting evidence-based decision making for national immunisation programs. Vaccine, 2010, 28(Suppl. 1):A1–110 (also available from http://www.sciencedirect.com/science/issue/5188-2010-999719999.8998-1900719).

3

4

2010 Pfizer GlaxoSmithKline

/

/ .2013 / . (SAGE)

10≥ 10≥ 2010 /

30 30 2012

. .

2015

2011

) (DTP3) %70 . (

. ) 2015

2.6

2015 2010

(B

–B 5

41 ) [HPV] 4.2

47

18

(A . .2010

(2 . (3 .

(1 : . .

5 7.5 . 2008 %92 2009 2000 .2010 . 6

.

10

%75

2008

: .

.

(1 : (3 .2008 " (4 . (6 . (5 . . " (2 .

. .

(1 : (2 . . (3 .

7

. ) .( .

2009

. .

2008

. 13 7 . 4 .

2010

/

24

.

8

(SAGE) . .

(SAGE)

.

(SAGE)

. .

(AEFI)

" .

" .

. . 9

. ) .(

.

.

.

(SAGE)

.

10

(SAGE)

. .

GACVS 4

2009

/

(SAGE) . 52010 (PCV)1 (

/

25

GACVS DNA )

.

(SAGE) DNA

(PCV)1 PCV1 DNA

.Rotarix

5

36-29 ،2010 ،5 ‫ر‬ ‫ا‬ Global Advisory Committee on Vaccine Safety. Statement of the Global Advisory Committee on Vaccine Safety on Rotarix. Geneva, World Health Organization, 2010 , accessed http://www.who.int/vaccine_safety/topics/rotavirus/rotarix_statement_march_2010/en/index.html( May 2010).

4

11

(

50000 .(

) 60 )

(SAGE) GACVS Rotarix . .76 .

5 .

124 34 .( %64

. 90 ) . 106

6 7

‫ر‬ ‫ر‬

‫ا‬. 51/52, 2009, . 533–537. ‫ا‬. 32, 2007, . 285–296.

12

. 8 2005 . . . . 2011 /

.

.

.9

(SAGE)

.

.

PATH

Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies Geneva, World Health Organization, 2006 (WHO/IVB/05.19). (Also available at http://www.who.int/immunization/documents/WHO_IVB_05.19/en/index.html.) 9 ‫ إ‬/‫ن‬ 15 – 13 ‫ا ة‬ ‫ا‬ ‫ا‬ ‫ري ا‬ ‫ا اء ا‬ ‫ا ع‬، ‫ت وا اد ا‬ ‫وا‬ ‫ا‬ .2010 ، ‫ا‬ ‫ا‬ .‫ا‬ ، ،2010 (http://www.who.int/immunization/sage/previous_april2010/en/index1.html, accessed May 2010).

8

13

Health Systems Building Blocks

. 244 .

. . .

.

(SAGE

)

.

14

. ) B DTP [Hib] ) .( ( HPV ) : ( )

. . (SAGE ) .

(

)

. 2009 .10 /

(SAGE ) (SAGE )

10

532-517

،2009 ،50 ‫ر‬

‫ا‬

15

. 24 . 12

. 6 . . 6

6≤

.

. . . .

. 16

. (SAGE ) ( ) . .

3 ≤ . . . (SAGE ) : .

.

17

) (cocooning (SAGE ) .

(SAGE )

. .

. . (SAGE ) .

B

(SAGE ) . . 18

( (SAGE ) . .( )

)

RV144

rpg120 CRF-01E B

( .

) 11

1

.

: (2 .

. . intercurrent infections .

16395 (1 CD4+ T

125 (P=0.039)

%31.2 .

.

(74) . CD4+ T

51

11

11 Rerks-Ngarm S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine, 2009, 361:2209–2220. (Also available from http://content.nejm.org/cgi/content/full/NEJMoa0908492.)

19

. . .( %99 %33) CD4+ T

(1 ≥) (3 . ( 12 (2 . %60

.

RV144 . (SAGE ) .

21

20

/

.2010

/

23 .2010

(SAGE ) . . . .

(SAGE ) .2009 289 A(H1N1) H5N1

A(H5N1) 500 2009 (H1N1) 15 2003 / . . .

B

(SAGE ) .2990 ‫م‬ (H1N1)

21

. < .

350 <

570

.12% 70

1.37 %28 : .2009 /

2010 2010 /

/

.

2009 -(H1N1)

. / . 94 12

2010

Wood DJ, et al. Update on H1N1 vaccine immunogenicity, safety and effectiveness. Geneva, World Health Organization, 2010 (http://www.who.int/immunization/sage/Influenza_2_H1N1_vaccine_immunogenicity_D_Wood_SAGE_April_201 0.pdf,; accessed May 2010).

22

. .2010 . /

48 46 22

74

(SAGE ) 500000 250000 . .13 . ) 56.19 ( . ( %75 ) 2011 /

H1N1 .2010 / (SAGE ) . 13

(SAGE )

(SAGE )

Shindo N. Global seasonal influenza disease burden and implementation of WHA 56.19. Geneva, World Health Organization, 2010 (http://www.who.int/immunization/sage/Influenza_4_WHA56.19_N_Shindo_SAGE_April_2010.pdf, accessed May 2010).

23

H1N1 (SAGE ) H5N1 / .H1N1 .2010

(SAGE )

.

(SAGE ) . . (GRADE) (GRADE) . 24

2008

(GRADE) . (GRADE) .

. (SAGE )

.

GRADE )

(SAGE )

( . . . . GRADE

25

(SAGE ) GRADE

. . Bradford-Hill

(SAGE ) . .GRADE

(SAGE )

2015 .

2010

26

(SAGE )

.

.

(SAGE ) . . (1 : .( 6 ) 3 (2 (3 . 2012 2010

(4 . .

27

2010 . . 6

.

(SAGE )

. 1.4 .2012 2010

.

28

(SAGE ) 14

.2010

/

Polio vaccines and routine polio immunization in the pre-eradication era [draft]. Geneva, World Health Organization, 2010 (http://www.who.int/immunization/sage/WHO_position_paper_on_polio_vaccines__Draft_2_March_2010.pdf, accessed May 2010).

14

29

Key facts
Document type Journal articles
Adoption date
Source World Health Organization